Robert Wessman, who was previously CEO of Actavis, has been appointed as executive chairman at Alvogen Group. Wessman was in charge of Actavis during a period that the company made a number of acquisitions to establish itself in the generic market.
The Economist dubbed Wessman the “Viking boss” during his time at Actavis. He will now attempt to ensure growth at Alvogen.
Daniel Movens has resigned from his position as CEO of Caraco. Jitendra Doshi is now the company’s interim CEO.
Doshi also served as interim CEO from 2003 to 2005. He has worked for Caraco in various executive capacities since 2001.
Mylan has appointed Heather Bresch has its president. Bresch has worked at Mylan for 17 years, most recently as chief operating officer, and will now take on additional leadership responsibilities.
In addition Rajiv Malik has been appointed as chief operating officer at Mylan. Malik was previously Mylan’s head of global technical operations.
Mylan has also appointed Timothy Sawyer as senior VP of strategic corporate development.
MeadWestvaco (MWV) has appointed Julia Amadio as its vice president (VP) of global marketing. In this capacity Amadio will be responsible for driving growth in emerging markets, China and India in particular.
Amadio was cofounder of JMA Consulting and has previously worked at companies including Parexel, Aventis and Wyeth.
Craig Phillips has been appointed as VP and general manager of the oncology business unit at Cephalon. Phillips joined Cephalon in 2007 and prior to that worked at Johnson & Johnson for 15 years.
Brookstone Pharmaceuticals has appointed Phillip Vogt as executive VP, sales and marketing. Vogt has worked in the pharma industry for more than 30 years at companies including Ethex.
Winston Pharmaceuticals has appointed Jeffrey Bernstein as CEO. Jeffrey Bernstein replaces Joel Bernstein, who founded the company. In addition Robert Yolles has become chairman of the board.
Dave Iwanicki has been appointed as senior VP, corporate development at EKR Therapeutics. Iwanicki joined EKR in 2008 and previously worked at Eli Lilly for 15 years.
BioWa has appointed Marc Silver as VP, corporate development.